John F. Milligan
Net Worth
Last updated:
What is John F. Milligan net worth?
The estimated net worth of Dr. John F. Milligan is at least $931,200 as of 15 Dec 2020. He owns shares worth $652,000 as insider and has received compensation worth at least $279,200 in 4D Molecular Therapeutics, Inc..
What is the salary of John F. Milligan?
Dr. John F. Milligan salary is $55,840 per year as Executive Chairman in 4D Molecular Therapeutics, Inc..
How old is John F. Milligan?
Dr. John F. Milligan is 64 years old, born in 1961.
What stocks does John F. Milligan currently own?
As insider, Dr. John F. Milligan owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| 4D Molecular Therapeutics, Inc. (FDMT) | Executive Chairman | 100,000 | $6.52 | $652,000 |
What does 4D Molecular Therapeutics, Inc. do?
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.
John F. Milligan insider trading
4D Molecular Therapeutics key executives
4D Molecular Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. David E. Schaffer Ph.D. (55) Co-Founder, Chief Scientific Advisor & Independent Director
- Dr. David H. Kirn (62) Co-Founder, Chief Executive Officer, Pres & Director
- Dr. John F. Milligan (64) Executive Chairman
- Dr. Robert S. Fishman (63) Chief Medical Officer & Therapeutic Area Head of Pulmonology
- Mr. August J. Moretti Esq., J.D. (74) Chief Financial Officer